{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T13:40:52Z","timestamp":1781790052502,"version":"3.54.5"},"reference-count":38,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T00:00:00Z","timestamp":1685318400000},"content-version":"unspecified","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science & Technology Commission","doi-asserted-by":"crossref","award":["Z201100005520029"],"award-info":[{"award-number":["Z201100005520029"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Corticosteroid is one of the most commonly used medications in patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD). The increasing understanding of these side-effects of systematic corticosteroids and their better response to treatment among patients with COPD with higher blood eosinophil counts has led to an interest in a more targeted approach to systematic corticosteroid treatment. However, there is a lack of evidence from high-quality randomised controlled trial (RCT) studies about whether initial systematic corticosteroids should be given to patients with AECOPD with elevated eosinophilia. The aim of the present research was to test this hypothesis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and analysis<\/jats:title><jats:p>This is a multicentre, double-blind, superiority RCT in the respiratory departments of 12 general hospitals in China. It is anticipated that 456 patients with AECOPD with a blood eosinophil count &gt;2%\u2009or &gt;300\u2009cells\/\u00b5L at admission will be recruited. Eligible patients will be randomised (1:1) to the intervention group receiving 40\u2009mg oral prednisone daily or identical-appearing placebo (control group) for five consecutive days. Follow-up visits are performed during hospitalisation, followed by clinic interviews on days 30, 60 and 90 after discharge. The primary outcome is treatment failure rates comprising requiring or receiving invasive or non-invasive mechanical ventilation, requiring or transferring to intensive care unit during the index hospitalisation, length of index hospitalisation longer than 14 days, death during the index hospitalisation or within 30 days after discharge and readmission with acute exacerbations of COPD within 30 days after discharge. The results of this trial will provide insight into the value of using blood eosinophil counts as a biomarker of eosinophilic exacerbation and initiating systematic corticosteroid treatment for patients with AECOPD with higher eosinophil levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Ethics and dissemination<\/jats:title><jats:p>This study was approved by Beijing Chaoyang Hospital Institutional Review Board (approval number: 2020-KE-544) and the main results and secondary results will be published in peer-reviewed journals.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration number<\/jats:title><jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"isrctn\" xlink:href=\"NCT05059873\">NCT05059873<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2022-066354","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T03:17:58Z","timestamp":1707967078000},"page":"e066354","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Multicentre double-blind randomised controlled trial of systematic corticosteroid therapy in patients with acute exacerbations of chronic obstructive pulmonary disease admitted to hospital with higher eosinophil levels: the ECHO protocol"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"isrctn05059873","registry":"10.18810\/isrctn"}],"author":[{"given":"Lirong","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxiang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6134-4937","authenticated-orcid":false,"given":"Lin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengmo","family":"Rong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuilian","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuxiang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5341-6857","authenticated-orcid":false,"given":"Zhaohui","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,5,29]]},"reference":[{"key":"2024020708320039000_13.5.e066354.1","doi-asserted-by":"crossref","first-page":"ITC17","DOI":"10.7326\/AITC202008040","article-title":"Chronic obstructive pulmonary disease","volume":"173","author":"Labaki","year":"2020","journal-title":"Annals of Internal Medicine"},{"key":"2024020708320039000_13.5.e066354.2","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.mcna.2018.12.005","article-title":"Chronic obstructive pulmonary disease: evaluation and management","volume":"103","author":"Duffy","year":"2019","journal-title":"Med Clin North Am"},{"key":"2024020708320039000_13.5.e066354.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2013.11.001"},{"key":"2024020708320039000_13.5.e066354.4","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.157.5.9709032"},{"key":"2024020708320039000_13.5.e066354.5","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S2213-2600(19)30176-6","article-title":"Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trial","volume":"7","author":"Sivapalan","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2024020708320039000_13.5.e066354.6","unstructured":"Expert consensus on diagnosis and treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in china (2017 update edition). International Respiratory Journal 2021."},{"key":"2024020708320039000_13.5.e066354.7","doi-asserted-by":"publisher","DOI":"10.2165\/11535220-000000000-00000"},{"key":"2024020708320039000_13.5.e066354.8","doi-asserted-by":"publisher","DOI":"10.7326\/M20-0432"},{"key":"2024020708320039000_13.5.e066354.9","doi-asserted-by":"crossref","unstructured":"Waljee AK , Rogers MAM , Lin P , et al . Short term use of oral corticosteroids and related harms among adults in the united states: population based cohort study. BMJ 2017;357:j1415. doi:10.1136\/bmj.j1415","DOI":"10.1136\/bmj.j1415"},{"key":"2024020708320039000_13.5.e066354.10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.5023"},{"key":"2024020708320039000_13.5.e066354.11","doi-asserted-by":"crossref","unstructured":"Walters JAE , Tan DJ , White CJ , et al . Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014;2014:CD001288. doi:10.1002\/14651858.CD001288.pub4","DOI":"10.1002\/14651858.CD001288.pub4"},{"key":"2024020708320039000_13.5.e066354.12","doi-asserted-by":"crossref","unstructured":"GOLD reports - global initiative for chronic obstructive lung disease; 2022. GOLD 12. doi:10.1038\/s41598-021-04756-w","DOI":"10.1038\/s41598-021-04756-w"},{"key":"2024020708320039000_13.5.e066354.13","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S2213-2600(17)30445-9","article-title":"Eosinophils in COPD: are we nearly there yet?","volume":"5","author":"Bafadhel","year":"2017","journal-title":"The Lancet Respiratory Medicine"},{"key":"2024020708320039000_13.5.e066354.14","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S2213-2600(17)30217-5","article-title":"Eosinophils in COPD: just another biomarker?","volume":"5","author":"Bafadhel","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2024020708320039000_13.5.e066354.15","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.chest.2019.02.406","article-title":"Low and high blood eosinophil counts as biomarkers in hospitalized acute exacerbations of COPD","volume":"156","author":"MacDonald","year":"2019","journal-title":"Chest"},{"key":"2024020708320039000_13.5.e066354.16","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2020-215167"},{"key":"2024020708320039000_13.5.e066354.17","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00062614"},{"key":"2024020708320039000_13.5.e066354.18","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201108-1553OC"},{"key":"2024020708320039000_13.5.e066354.19","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/resp.13660","article-title":"Blood eosinophil count as a predictor of hospital length of stay in COPD exacerbations","volume":"25","author":"Ko","year":"2020","journal-title":"Respirology"},{"key":"2024020708320039000_13.5.e066354.20","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00651-2019"},{"key":"2024020708320039000_13.5.e066354.21","unstructured":"GOLD reports - global initiative for chronic obstructive lung disease; 2021. GOLD"},{"key":"2024020708320039000_13.5.e066354.22","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.chest.2016.01.026","article-title":"Blood eosinophils and outcomes in severe hospitalized exacerbations of COPD","volume":"150","author":"Bafadhel","year":"2016","journal-title":"Chest"},{"key":"2024020708320039000_13.5.e066354.23","doi-asserted-by":"crossref","unstructured":"Zhan Z, Y , Zeng Z , et al . Blood eosinophils and clinical outcomes in patients with acute exacerbation of chronic obstructive pulmonary disease: A propensity score matching analysis of real-world data in china. Front Med Lausanne 2021. doi:10.3389\/fmed.2021.653777","DOI":"10.3389\/fmed.2021.653777"},{"key":"2024020708320039000_13.5.e066354.24","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200801-145OC"},{"key":"2024020708320039000_13.5.e066354.25","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S2213-2600(14)70019-0","article-title":"Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Uzun","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2024020708320039000_13.5.e066354.26","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201005-0762OC"},{"key":"2024020708320039000_13.5.e066354.27","doi-asserted-by":"publisher","DOI":"10.1136\/thx.54.7.581"},{"key":"2024020708320039000_13.5.e066354.28","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00102509"},{"key":"2024020708320039000_13.5.e066354.29","doi-asserted-by":"publisher","DOI":"10.1378\/chest.85.6.751"},{"key":"2024020708320039000_13.5.e066354.30","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/28.5.333"},{"key":"2024020708320039000_13.5.e066354.31","doi-asserted-by":"crossref","unstructured":"Scichilone N, L , Spatafora M , et al . Blood eosinophils and treatment response in hospitalized exacerbations of chronic obstructive pulmonary disease: A case-control study. Pulm Pharmacol Ther 2016:3789\u201394. doi:10.1016\/j.pupt.2016.03.004","DOI":"10.1016\/j.pupt.2016.03.004"},{"key":"2024020708320039000_13.5.e066354.32","doi-asserted-by":"crossref","unstructured":"Mathioudakis AG , Abroug F , Agusti A , et al . ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations. Eur Respir J 2022;59:2102006. doi:10.1183\/13993003.02006-2021","DOI":"10.1183\/13993003.02006-2021"},{"key":"2024020708320039000_13.5.e066354.33","doi-asserted-by":"crossref","unstructured":"Suehs CM , Zysman M , Chenivesse C , et al . Prioritising outcomes for evaluating eosinophil-guided corticosteroid therapy among patients with acute COPD exacerbations requiring hospitalisation: a delphi consensus study. BMJ Open 2020;10:e035811. doi:10.1136\/bmjopen-2019-035811","DOI":"10.1136\/bmjopen-2019-035811"},{"key":"2024020708320039000_13.5.e066354.34","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3389\/fphar.2019.00765","article-title":"Eosinophil inflammation and hyperresponsiveness in the airways as phenotypes of COPD, and usefulness of inhaled glucocorticosteroids","volume":"10","author":"Kume","year":"2019","journal-title":"Front Pharmacol"},{"key":"2024020708320039000_13.5.e066354.35","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00427-2018"},{"key":"2024020708320039000_13.5.e066354.36","doi-asserted-by":"crossref","unstructured":"Huang W-C , Huang C-C , Wu P-C , et al . The association between airflow limitation and blood eosinophil levels with treatment outcomes in patients with chronic obstructive pulmonary disease and prolonged mechanical ventilation. Sci Rep 2019;9:13420. doi:10.1038\/s41598-019-49918-z","DOI":"10.1038\/s41598-019-49918-z"},{"key":"2024020708320039000_13.5.e066354.37","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.2147\/COPD.S165909","article-title":"Longitudinal stability of blood eosinophil count strata in the COPD COSYCONET cohort","volume":"13","author":"Greulich","year":"2018","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2024020708320039000_13.5.e066354.38","doi-asserted-by":"crossref","first-page":"20406223211028770","DOI":"10.1177\/20406223211028768","article-title":"Blood eosinophil count-guided corticosteroid therapy and as a prognostic biomarker of exacerbations of chronic obstructive pulmonary disease: a systematic review and meta-analysis","volume":"12","author":"Liu","year":"2021","journal-title":"Ther Adv Chronic Dis"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-066354","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T03:18:14Z","timestamp":1707967094000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-066354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":38,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5,29]]},"published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1136\/bmjopen-2022-066354"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-066354","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5]]}}}